CARA vs. LEXX, XLO, UNCY, SNSE, PMN, VYNE, CASI, EYEN, GANX, and MRKR
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Lexaria Bioscience (LEXX), Xilio Therapeutics (XLO), Unicycive Therapeutics (UNCY), Sensei Biotherapeutics (SNSE), ProMIS Neurosciences (PMN), VYNE Therapeutics (VYNE), CASI Pharmaceuticals (CASI), Eyenovia (EYEN), Gain Therapeutics (GANX), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical preparations" industry.
Cara Therapeutics (NASDAQ:CARA) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.
Cara Therapeutics received 664 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 75.00% of users gave Cara Therapeutics an outperform vote.
Cara Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
In the previous week, Cara Therapeutics had 12 more articles in the media than Lexaria Bioscience. MarketBeat recorded 14 mentions for Cara Therapeutics and 2 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.46 beat Cara Therapeutics' score of -0.15 indicating that Lexaria Bioscience is being referred to more favorably in the news media.
44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 7.6% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Lexaria Bioscience has lower revenue, but higher earnings than Cara Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lexaria Bioscience has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. Lexaria Bioscience's return on equity of -133.97% beat Cara Therapeutics' return on equity.
Cara Therapeutics presently has a consensus target price of $11.12, indicating a potential upside of 1,382.47%. Lexaria Bioscience has a consensus target price of $12.00, indicating a potential upside of 280.95%. Given Cara Therapeutics' higher probable upside, equities research analysts plainly believe Cara Therapeutics is more favorable than Lexaria Bioscience.
Summary
Lexaria Bioscience beats Cara Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
